BBIO · BridgeBio Pharma, Inc.
$84.13
+0.01 (+0.01%)
At close · Jul 28
Market Cap
$16.48B
Shares
195.86M
BridgeBio Pharma, Inc. Earnings Call Transcripts
Every quarterly earnings call for BridgeBio Pharma, Inc. (BBIO) — the full transcript with speaker labels, the audio replay, AI call highlights and a management-tone score, plus the matching 8-K earnings release and the quarter's 10-Q or 10-K. Investor days and conferences appear here too.
Revenue & result across quarters
Revenue Net income YoY up YoY down artefacts
·
$54.02M
−$102.07M
'21 Q2
21-08-13
·
$12.89M
−$152.28M
'21 Q4
22-03-14
▲266.7%
$1.69M
−$201.33M
'22 Q1
22-05-18
▼85.5%
$1.87M
−$140.57M
'22 Q4
23-02-23
▼97.8%
$1.64M
−$160.70M
'23 Q2
23-08-28
▲1110.4%
$4.09M
−$179.49M
'23 Q3
23-11-12
▲11461.9%
$211.12M
−$36.16M
'24 Q1
24-05-29
▼33.2%
$2.73M
−$164.25M
'24 Q3
24-11-23
▲237.1%
$5.88M
−$267.39M
'24 Q4
25-01-13
▼44.8%
$116.63M
−$169.61M
'25 Q1
25-04-29
▲4999.9%
$110.56M
−$183.76M
'25 Q2
25-08-05
▲4318%
$120.70M
−$184.94M
'25 Q3
25-10-29
▲2521.2%
$154.18M
−$194.63M
'25 Q4
26-02-24
LATEST
▲66.8%
$194.51M
−$166.56M
'26 Q1
26-05-07
Conference
Investor event
2026-06-09
Goldman Sachs 47th Annual Global Healthcare Conference
No reported result — non-financial event
Audio
Transcript
Slides
Conference
Investor event
2026-06-04
2026 Jefferies Global Healthcare Conference
No reported result — non-financial event
Audio
Transcript
Slides
Conference
Investor event
2026-05-12
BoA Securities Health Care Conference 2026
No reported result — non-financial event
Audio
Transcript
Slides
Earnings call
FY26 · Q1
2026-05-07
BridgeBio Pharma, Inc. Q1 FY2026 Earnings Call
Confident tone
Atruvio (acoramidis) commercial momentum
Encaleret in ADH1 and chronic hypoparathyroidism
Infigratinib for achondroplasia
Revenue
$194.51M
▲ 66.8% YoY Diluted EPS
$-0.84
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Conference
Investor event
2026-03-11
Barclays 28th Annual Global Healthcare Conference
No reported result — non-financial event
Audio
Transcript
Slides
Conference
Investor event
2026-03-10
Leerink Partners Global Healthcare Conference
No reported result — non-financial event
Audio
Transcript
Slides
Conference
Investor event
2026-03-02
TD Cowen 46th Annual Healthcare Conference
No reported result — non-financial event
Audio
Transcript
Slides
Earnings call
FY25 · Q4
2026-02-24
BridgeBio Pharma, Inc. Q4 FY2025 Earnings Call
Confident tone
Atruby / ATTR cardiomyopathy commercial launch
Pipeline and Phase 3 catalysts
Tafamidis IP risk
Revenue
$154.18M*
▲ 2521.2% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Conference
Investor event
2026-01-12
44th Annual J.P. Morgan Healthcare Conference
No reported result — non-financial event
Audio
Transcript
Slides
Conference
Investor event
2025-12-03
8th Annual Evercore Healthcare Conference
No reported result — non-financial event
Audio
Transcript
Slides
Conference
Investor event
2025-11-18
Jefferies Global Healthcare Conference
No reported result — non-financial event
Audio
Transcript
Slides
Earnings call
FY25 · Q3
2025-10-29
BridgeBio Pharma, Inc. Q3 FY2025 Earnings Call
Confident tone
Attruby commercial performance
Infigratinib in achondroplasia
Encaleret Phase III CALIBRATE in ADH1
Revenue
$120.70M
▲ 4318% YoY Diluted EPS
$-0.95
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY25 · Q2
2025-08-05
BridgeBio Pharma, Inc. Q2 FY2025 Earnings Call
Confident tone
Attruby commercial launch
Late-stage pipeline readouts
Clinical differentiation and best-in-class data
Revenue
$110.56M
▲ 4999.9% YoY Diluted EPS
$-0.95
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY25 · Q1
2025-04-29
BridgeBio Pharma, Inc. Q1 FY2025 Earnings Call
Confident tone
Late-stage pipeline readouts
Pipeline expansion indications
TTR competitive positioning vs Acoramidis
Revenue
$116.63M
▼ 44.8% YoY Diluted EPS
$-0.88
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY24 · Q4
2025-01-13
BridgeBio Pharma, Inc. Q4 FY2024 Earnings Call
Revenue
$5.88M*
▲ 237.1% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY24 · Q3
2024-11-23
BridgeBio Pharma, Inc. Q3 FY2024 Earnings Call
Revenue
$2.73M
▼ 33.2% YoY Diluted EPS
$-0.86
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY24 · Q1
2024-05-29
BridgeBio Pharma, Inc. Q1 FY2024 Earnings Call
Revenue
$211.12M
▲ 11461.9% YoY Diluted EPS
$-0.20
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY23 · Q3
2023-11-12
BridgeBio Pharma, Inc. Q3 FY2023 Earnings Call
Revenue
$4.09M
▲ 1110.4% YoY Diluted EPS
$-1.08
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY23 · Q2
2023-08-28
BridgeBio Pharma, Inc. Q2 FY2023 Earnings Call
Revenue
$1.64M
▼ 97.8% YoY Diluted EPS
$-0.98
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY22 · Q4
2023-02-23
BridgeBio Pharma, Inc. Q4 FY2022 Earnings Call
Revenue
$1.87M*
▼ 85.5% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY22 · Q1
2022-05-18
BridgeBio Pharma, Inc. Q1 FY2022 Earnings Call
Revenue
$1.69M
▲ 266.7% YoY
Rev · 6q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY21 · Q4
2022-03-14
BridgeBio Pharma, Inc. Q4 FY2021 Earnings Call
Revenue
$12.89M*
Rev · 5q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY21 · Q2
2021-08-13
BridgeBio Pharma, Inc. Q2 FY2021 Earnings Call
Revenue
$54.02M
Rev · 4q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY20 · Q4
2021-03-22
BridgeBio Pharma, Inc. Q4 FY2020 Earnings Call
Results not yet reported
Audio
Transcript
Slides
8-K10-K
Earnings call
FY20 · Q2
2020-08-11
BridgeBio Pharma, Inc. Q2 FY2020 Earnings Call
Results not yet reported
Audio
Transcript
Slides
8-K10-Q
Showing 1–25 of 25 earnings calls
Key facts
CIK
1743881
CUSIP
10806X102
13F (30d)
85 filings
84 filers
Visit website
Investor relations